Recent Updates
Recently added Catalysts
SIBN Positive Sentiment

SI-BONE To Report Second Quarter 2024 Financial Results on August 5, 2024

Key Takeaway: SI-BONE, Inc. has announced the reporting date for its second quarter 2024 financial results, which will take place after market close on August 5, 2024. Management will hold a conference call to discuss these results, starting at 1:30 p.m. Pacific Time. SI-BONE is recognized for its advanced technologies in surgical treatments for musculoskeletal disorders, having supported numerous surgeons and published substantial clinical evidence regarding its products.
Price reaction · baseline $15.32 (2024-07-12 close) · clean, no other SIBN news in the window
day 0 close · peak
+1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE is a leader in innovative surgical technology for musculoskeletal issues.
  • The company has extensive clinical evidence supporting its products.
  • SI-BONE has a strong track record with over 100,000 successful procedures.

Full Press Release Details

SANTA CLARA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2024 after market close on Monday, August 5, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/bdg2s7zw. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 3,700 surgeons in performing a total of more than 100,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including four randomized controlled trials and over 130 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

Frequently Asked Questions

When will SI-BONE report its Q2 2024 financial results?

SI-BONE will report its Q2 2024 financial results on August 5, 2024.

What time is the SI-BONE conference call scheduled?

The conference call is set for 1:30 p.m. PT / 4:30 p.m. ET.

How can I listen to the SI-BONE conference call?

Investors can register to listen at the provided registration link.

How long will the SI-BONE webcast be available for replay?

The webcast will be archived for at least 90 days post-event.

What does SI-BONE specialize in?

SI-BONE focuses on surgical treatments for musculoskeletal disorders.

Last updated: Jul 15, 2024